Parkin Antikörper (C-Term)

Produktnummer ABIN928012

Produktdetails anti-Parkin Antikörper

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Bindungsspezifität: C-Term

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Parkin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Kreuzreaktivität: Maus

Aufreinigung: Purified

Immunogen: Park2 antibody was raised in rabbit using the C terminal of Park2 as the immunogen

Anwendungsinformationen

Applikationshinweise: WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator.

Kommentare:

Park2 Blocking Peptide, catalog no. 33R-10267, is also available for use as a blocking control in assays to test for specificity of this Park2 antibody

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Konzentration: Lot specific

Buffer: Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C, following reconstitution, aliquot and store at -20 °C.

Details zu Parkin

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Andere Bezeichnung: Park2 (PARK2 Produkte)

Synonyme: CG10523 antikoerper, Dmel\\CG10523 antikoerper, Dpark antikoerper, SD01679 antikoerper, dpk antikoerper, AR-JP antikoerper, LPRS2 antikoerper, PDJ antikoerper, PRKN antikoerper, Park antikoerper, Prkn antikoerper, si:ch211-123f21.1 antikoerper, zgc:112390 antikoerper, pdr-1 antikoerper, PARK2 antikoerper, parkin antikoerper, parkin RBR E3 ubiquitin protein ligase antikoerper, Parkinson disease (autosomal recessive, juvenile) 2, parkin antikoerper, park antikoerper, PRKN antikoerper, Prkn antikoerper, prkn antikoerper, CpipJ_CPIJ014867 antikoerper, Park2 antikoerper

Hintergrund: Park2 functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5 and AIMP2. Park2 may play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Park2 limits the production of reactive oxygen species (ROS). Synonyms: Polyclonal Park2 antibody, Anti-Park2 antibody, Parkinson disease, autosomal recessive, juvenile 2, parkin antibody, MGC130518 antibody, PRKN antibody.

Pathways: Autophagie, Ubiquitin Proteasome Pathway